Could drug price transparency raise prices? These lobbyists and lawmakers think so.

Market Watch

21 May 2019 - Objections made on disclosing rebates and revealing data about free samples.

As Washington tries to address soaring drug prices, even efforts to just bring more transparency to the state of affairs aren’t a slam dunk.

At a House subcommittee hearing on Tuesday, interest groups and Republican law makers voiced concerns about bills promising more sunshine.

Read Market Watch article 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Pricing , Transparency